KR101252866B1 - 암 치료를 위한 화합물 및 방법 - Google Patents

암 치료를 위한 화합물 및 방법 Download PDF

Info

Publication number
KR101252866B1
KR101252866B1 KR1020077003723A KR20077003723A KR101252866B1 KR 101252866 B1 KR101252866 B1 KR 101252866B1 KR 1020077003723 A KR1020077003723 A KR 1020077003723A KR 20077003723 A KR20077003723 A KR 20077003723A KR 101252866 B1 KR101252866 B1 KR 101252866B1
Authority
KR
South Korea
Prior art keywords
delete delete
cancer
alkyl
cells
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077003723A
Other languages
English (en)
Korean (ko)
Other versions
KR20070046120A (ko
Inventor
랄프 에이. 징가로
하티스 더츠케일
에밀 제이. 프리레이치
하곱 칸타르지안
메리다 소텔로-라마
소르단 베르스토프세크
밍쯔항 가오
Original Assignee
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템
더 텍사스 에이 & 엠 유니버시티 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템, 더 텍사스 에이 & 엠 유니버시티 시스템 filed Critical 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템
Publication of KR20070046120A publication Critical patent/KR20070046120A/ko
Application granted granted Critical
Publication of KR101252866B1 publication Critical patent/KR101252866B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/72—Aliphatic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/74—Aromatic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/80—Heterocyclic compounds
    • C07F9/82—Arsenic compounds containing one or more pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020077003723A 2004-07-16 2005-07-15 암 치료를 위한 화합물 및 방법 Expired - Fee Related KR101252866B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58859604P 2004-07-16 2004-07-16
US60/588,596 2004-07-16
PCT/US2005/025192 WO2006020048A2 (en) 2004-07-16 2005-07-15 Compounds and methods for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020127030429A Division KR20130001323A (ko) 2004-07-16 2005-07-15 암 치료를 위한 화합물 및 방법

Publications (2)

Publication Number Publication Date
KR20070046120A KR20070046120A (ko) 2007-05-02
KR101252866B1 true KR101252866B1 (ko) 2013-04-10

Family

ID=35414967

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020077003723A Expired - Fee Related KR101252866B1 (ko) 2004-07-16 2005-07-15 암 치료를 위한 화합물 및 방법
KR1020127030429A Ceased KR20130001323A (ko) 2004-07-16 2005-07-15 암 치료를 위한 화합물 및 방법
KR1020147000020A Withdrawn KR20140013110A (ko) 2004-07-16 2005-07-15 암 치료를 위한 화합물 및 방법
KR1020147030246A Ceased KR20140136525A (ko) 2004-07-16 2005-07-15 암 치료를 위한 화합물 및 방법
KR1020137021239A Ceased KR20130095857A (ko) 2004-07-16 2005-07-15 암 치료를 위한 화합물 및 방법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020127030429A Ceased KR20130001323A (ko) 2004-07-16 2005-07-15 암 치료를 위한 화합물 및 방법
KR1020147000020A Withdrawn KR20140013110A (ko) 2004-07-16 2005-07-15 암 치료를 위한 화합물 및 방법
KR1020147030246A Ceased KR20140136525A (ko) 2004-07-16 2005-07-15 암 치료를 위한 화합물 및 방법
KR1020137021239A Ceased KR20130095857A (ko) 2004-07-16 2005-07-15 암 치료를 위한 화합물 및 방법

Country Status (11)

Country Link
US (2) US7405314B2 (enExample)
EP (1) EP1771459A2 (enExample)
JP (3) JP5618461B2 (enExample)
KR (5) KR101252866B1 (enExample)
CN (3) CN104163833A (enExample)
AU (1) AU2005274926B2 (enExample)
CA (2) CA2574032C (enExample)
HK (1) HK1204476A1 (enExample)
IL (2) IL180729A (enExample)
TW (3) TW201440760A (enExample)
WO (1) WO2006020048A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057012A2 (en) 2002-01-07 2003-07-17 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
US7628810B2 (en) 2003-05-28 2009-12-08 Acufocus, Inc. Mask configured to maintain nutrient transport without producing visible diffraction patterns
TW201440760A (zh) 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
EP2394702B1 (en) * 2005-07-29 2014-12-31 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
EP1979368B1 (en) * 2006-01-13 2014-12-24 The Texas A&M University System Compounds and methods for the treatment of cancer
RU2318519C2 (ru) * 2006-03-06 2008-03-10 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ химиотерапии острого лейкоза
TW200829261A (en) * 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
CA2704395A1 (en) * 2007-11-02 2009-05-14 Ziopharm Oncology, Inc. Combination therapy with organic arsenicals
BRPI0821002A2 (pt) * 2007-12-12 2015-06-16 Ziopharm Oncology Inc Compostos e métodos para o tratamento de câncer
PT2321012T (pt) * 2008-08-20 2019-01-11 Solasia Pharma K K Compostos organoarsénicos e métodos para o tratamento de cancro
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
US10004593B2 (en) 2009-08-13 2018-06-26 Acufocus, Inc. Intraocular lens with elastic mask
BR112012008083A2 (pt) 2009-08-13 2016-04-19 Acufocus Inc lentes e implantes intraoculares ocultos
EP2717884A1 (en) 2011-06-06 2014-04-16 Chevron Phillips Chemical Company LP Use of metallocene compounds for cancer treatment
US9545303B2 (en) 2011-12-02 2017-01-17 Acufocus, Inc. Ocular mask having selective spectral transmission
US9427922B2 (en) 2013-03-14 2016-08-30 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
TWI617305B (zh) * 2013-12-05 2018-03-11 蘇愛康制藥有限公司 治療癌症的化合物及其應用程序
GB201418491D0 (en) * 2014-10-17 2014-12-03 Monfort University De Compounds
US9943403B2 (en) 2014-11-19 2018-04-17 Acufocus, Inc. Fracturable mask for treating presbyopia
ES2972581T3 (es) 2015-10-05 2024-06-13 Acufocus Inc Métodos de moldeo de lentes intraoculares
CN108431676B (zh) 2015-11-24 2022-01-04 阿库福库斯公司 具有延伸的焦深的复曲面小孔口人工晶状体
CN105330701B (zh) * 2015-11-27 2017-05-31 昆明医科大学 一种含砷化合物及其制备方法和应用
EP3790508A4 (en) 2018-05-09 2022-02-09 AcuFocus, Inc. INTRAOCULAR IMPLANT WITH REMOVABLE OPTICS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034095A1 (en) * 2002-01-07 2004-02-19 Zingaro Ralph A. S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE407683T1 (de) * 1997-10-15 2008-09-15 Polarx Biopharmaceuticals Inc Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von multiplen myelom
IL136051A0 (en) 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
US6191123B1 (en) * 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
EP1328253B1 (en) * 2000-04-26 2006-03-22 Oregon Health Sciences University Administration of a thiol-based chemoprotectant compound
TW201440760A (zh) * 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034095A1 (en) * 2002-01-07 2004-02-19 Zingaro Ralph A. S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer

Also Published As

Publication number Publication date
TW201440760A (zh) 2014-11-01
CN104163833A (zh) 2014-11-26
CN101076533B (zh) 2013-11-06
JP2014122233A (ja) 2014-07-03
JP5618461B2 (ja) 2014-11-05
CA2574032C (en) 2015-02-24
WO2006020048A3 (en) 2006-08-24
CA2574032A1 (en) 2006-02-23
US20080090793A1 (en) 2008-04-17
KR20140013110A (ko) 2014-02-04
HK1204476A1 (en) 2015-11-20
WO2006020048A2 (en) 2006-02-23
JP2008506710A (ja) 2008-03-06
WO2006020048B1 (en) 2006-10-19
AU2005274926B2 (en) 2011-04-28
TWI411431B (zh) 2013-10-11
AU2005274926A1 (en) 2006-02-23
US20060128682A1 (en) 2006-06-15
IL180729A0 (en) 2007-06-03
IL215896A0 (en) 2011-12-29
CN101076533A (zh) 2007-11-21
KR20070046120A (ko) 2007-05-02
KR20130001323A (ko) 2013-01-03
CA2777473C (en) 2013-08-27
TW201350113A (zh) 2013-12-16
US7405314B2 (en) 2008-07-29
CA2777473A1 (en) 2006-02-23
KR20140136525A (ko) 2014-11-28
EP1771459A2 (en) 2007-04-11
IL180729A (en) 2012-03-29
JP5745660B2 (ja) 2015-07-08
CN105777811A (zh) 2016-07-20
KR20130095857A (ko) 2013-08-28
JP2012051919A (ja) 2012-03-15
TW200616615A (en) 2006-06-01

Similar Documents

Publication Publication Date Title
KR101252866B1 (ko) 암 치료를 위한 화합물 및 방법
JP5603593B2 (ja) 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン
KR101471498B1 (ko) 암의 치료를 위한 화합물 및 방법
AU2011204901B2 (en) Compounds and methods for treatment of cancer
AU2007249110C1 (en) S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatment for cancer
HK1166959A (en) S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A17-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160404

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160404

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000